Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Common-sense precautions for H1N1

Doctors and hospitals nationwide expect a surge in H1N1 influenza cases during the upcoming flu season. In a new video and the tips below, Yvonne Maldonado, MD, chief of infectious disease at Lucile Packard Children’s Hospital at Stanford, explains what every parent should know about H1N1 flu as children head back to school.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

Computed tomography angiography can identify abnormalities and injury beyond the pulmonary arteries

Children with clinically suspected pulmonary embolism (PE) are increasingly being evaluated with CT angiography (CTA). Even though many children ultimately test negative for PE, study results suggest that CTA is still valuable for this indication because it has the ability to accurately detect a variety of alternative diagnoses.

19 Aug 2009

Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine

Sinovac Biotech Ltd. announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. Notably, Sinovac is the first company worldwide to complete clinical trials for the H1N1 vaccine.

19 Aug 2009

Novavax reports positive preclinical results for H1N1 influenza VLP vaccine

Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.

19 Aug 2009

Hard to Treat Diseases' swine flu clinical trials in progress

Hard to Treat Diseases (HTDS.PK) Mellow Hope, an operating subsidiary of HTDS, is pleased to report that its clinical trial is currently being processed.

19 Aug 2009

CSL Biotherapies to supply Afluria influenza vaccines from newly licensed packaging facility

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company’s newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL’s U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

H1N1 vaccine administration coverage from Anthem Blue Cross and Blue Shield in New Hampshire

Anthem Blue Cross and Blue Shield in New Hampshire has announced that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines.

19 Aug 2009

Two American Oriental Bioengineering products bag China's Top Branded Drugs of 2009 award

American Oriental Bioengineering, Inc. today announced that two of AOBO's branded products, Jinji Capsules and Boke Nasal Spray, were awarded the designation of "China's Top Branded Drugs of 2009" at an award ceremony held in Shanghai on August 11, 2009.

19 Aug 2009

George Rehm and David Mahoney joins Adamas' Board of Directors

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, the company announced the election of George M. Rehm, Managing Partner of aeris CAPITAL AG, and David L. Mahoney, a private equity investor, to the company's Board of Directors.

19 Aug 2009

Elsevier/Lancet launch H1N1 resource centre

An H1N1 influenza channel has been added to the Elsevier Global Medical News (EGMN) wire service division of the International Medical News Group. The H1N1 channel was created to meet physicians' continuing needs to keep up-to-date with the news about the spread of the 2009 H1N1 influenza virus, as well as the new diagnostics, vaccines, clinical trials, and treatments for H1N1 infections.

18 Aug 2009

Medicare pilot project links hospital payments to quality

Data to be released today examines a pilot project by Medicare that links hospital payments to the quality of care.

18 Aug 2009

H1N1 pandemic: no time for complacency

Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial.

18 Aug 2009

New guidance on novel H1N1 influenza for K-12 schools

The Secretary of Health today released guidance on Novel H1N1, also known as swine flu, for elementary and secondary schools in an effort to keep kids and staff healthy and flu-free this school year.

17 Aug 2009

Alpharx completes lyophilization process for Zysolin

AlphaRx Inc. has announced that it has completed the lyophilization process for Zysolin(TM), allowing the company to proceed to clinical batch material manufacturing for human trials. This process has been solely developed by AlphaRx's scientists and the resulting formulations have been successfully tested in animal studies conducted by the U.S. Army under a Material Transfer Agreement.

17 Aug 2009

GSK starts testing H1N1 vaccine; Opinion piece addresses U.S. role in helping developing countries procure vaccine

"GlaxoSmithKline has started testing its pandemic H1N1 swine flu vaccine in humans, and expects to start giving the results to government agencies next month, the drugmaker said on Friday," Reuters reports. The company "plans to conduct 16 different trials of the vaccine and to test 9,000 people in total across Europe, Canada and the United States," according to the news service (Deighton, 8/14).

17 Aug 2009

Biologist demystifies Acinetobacter baumannii

Tao Weitao, a researcher in the College of Sciences' Department of Biology at the University of Texas at San Antonio is making great strides in a project that was funded one year ago by the San Antonio Area Foundation. The professor in the South Texas Center for Emerging Infectious Diseases is researching Acinetobacter baumannii, a soil-dwelling bacterium that threatens the health of military personnel in the Middle East and can also infect their family members once the soldiers have returned home following battle.

17 Aug 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

New consortium to tackle African sleeping sickness and Leishmaniasis

A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide.

17 Aug 2009